多発性骨髄腫治療薬市場：薬剤別、流通別-2025-2030年の世界予測

多発性骨髄腫治療薬市場は、2023年に227億米ドルと評価され、2024年には245億1,000万米ドルに達すると予測され、CAGR 8.04％で成長し、2030年には390億2,000万米ドルに達すると予測されています。

多発性骨髄腫治療薬市場は、骨髄内の悪性形質細胞を特徴とする多発性骨髄腫として知られる血液がんの治療に使用される医薬品によって定義されます。多発性骨髄腫治療薬は、疾患管理と患者のQOL向上に不可欠です。多発性骨髄腫治療薬の必要性は、生存率を延ばし、症状を最小限に抑えるという役割に由来します。薬剤のカテゴリーには、プロテアソーム阻害剤、免疫調節剤、モノクローナル抗体などがあり、これらは最前線および再発治療レジメンに不可欠です。エンドユーザーは主に病院、専門クリニック、研究機関です。市場成長は、罹患率の上昇、生物製剤の進歩、研究開発投資の増加といった要因に影響されます。さらに、高齢者人口の増加や新興国市場におけるヘルスケアへのアクセスの拡大が、市場ダイナミクスをさらに際立たせています。最新のビジネスチャンスは、個別化医療のアプローチや、特に免疫チェックポイント阻害剤との併用療法に見られ、有効性の向上が期待できます。企業は、戦略的提携や未開拓の層における臨床試験の拡大を通じて、こうした機会を活用することができます。しかし、この市場は、高額な薬剤費、厳しい規制経路、患者のコンプライアンスに影響を及ぼす可能性のある副作用といった課題に直面しています。また、主要医薬品の特許切れによるバイオシミラーの流入など、競合情勢も競合の要因となっています。技術革新が必要な分野には、CAR T細胞治療などの次世代治療や、ナノキャリア技術などの新規ドラッグデリバリーシステムがあります。こうした技術革新は、治療の特異性を高め、副作用を軽減し、市場拡大を後押しします。同市場は、科学的イノベーションに支えられつつも、経済的・規制的ハードルによって制約を受けるという二面性を示しています。多発性骨髄腫治療薬市場において、規制の枠組みとの戦略的な整合、最先端の研究開発への投資、バイオテクノロジー企業とのパートナーシップの活用は、持続的な事業成長と患者の転帰向上のための効果的な手段となり得る。

市場力学：急速に進化する多発性骨髄腫治療薬市場の主要市場インサイトを公開

多発性骨髄腫治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 多発性骨髄腫の適応症と有病率の増加
  • 先進諸国の治療を支える魅力的な償還政策
  • ジェネリック医薬品の承認に伴う薬剤の入手可能性の増加
• 市場抑制要因
  • 厳しい医薬品承認プロセス
• 市場機会
  • 製品開発、臨床試験、商品化の共同開発
  • 標的治療と副腎皮質ステロイドの採用
• 市場の課題
  • 副作用の可能性

ポーターの5つの力：多発性骨髄腫治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：多発性骨髄腫治療薬市場における外部からの影響の把握

外部マクロ環境要因は、多発性骨髄腫治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析多発性骨髄腫治療薬市場における競合情勢の把握

多発性骨髄腫治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス多発性骨髄腫治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、多発性骨髄腫治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨多発性骨髄腫治療薬市場における成功への道筋を描く

多発性骨髄腫治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 多発性骨髄腫の適応症と有病率の増加
    • 先進国における治療を支援する魅力的な償還政策
    • ジェネリック医薬品の承認とともに医薬品の入手性が向上
  • 抑制要因
    • 厳格な医薬品承認プロセス
  • 機会
    • 製品開発と医薬品試験および商品化の連携
    • 標的療法とコルチコステロイドの導入
  • 課題
    • 潜在的な副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 多発性骨髄腫治療薬市場薬物別

• ヒストン脱アセチル化酵素阻害剤
• 免疫調節剤
• モノクローナル抗体
• プロテアソーム阻害剤

第7章 多発性骨髄腫治療薬市場配布元

• 病院薬局
• オンラインチャンネル
• 小売薬局

第8章 南北アメリカの多発性骨髄腫治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の多発性骨髄腫治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの多発性骨髄腫治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Accurex Health Care Manufacturing Inc.
• Amgen Inc.
• Bayer AG
• Bristol Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Limited
• Johnson & Johnson Services, Inc.
• Nichi-Iko Pharmaceutical Co., Ltd.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sandoz International GmbH
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 23. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 24. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 35. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 36. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 38. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 72. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 80. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 82. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 83. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 102. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 103. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Multiple Myeloma Drug Market was valued at USD 22.70 billion in 2023, expected to reach USD 24.51 billion in 2024, and is projected to grow at a CAGR of 8.04%, to USD 39.02 billion by 2030.

The multiple myeloma drugs market is defined by pharmaceuticals used to treat the blood cancer known as multiple myeloma, characterized by malignant plasma cells in the bone marrow. These drugs are vital for disease management and improving patient quality of life. The necessity of multiple myeloma drugs stems from their role in prolonging survival rates and minimizing symptoms. Drug categories include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, which are critical for frontline and relapsed treatment regimens. End-users primarily consist of hospitals, specialty clinics, and research institutions. Market growth is influenced by factors such as rising incidence rates, advancements in biologics, and increasing investment in R&D. Moreover, a growing geriatric population and expanding access to healthcare in developing regions further accentuate market dynamics. Latest opportunities are seen in personalized medicine approaches and combination therapies, notably with immune checkpoint inhibitors, that promise enhanced efficacy. Businesses can capitalize on these opportunities through strategic collaborations and expanding clinical trials in underexplored demographics. However, the market faces challenges such as high drug costs, stringent regulatory pathways, and potential adverse effects, which may affect patient compliance. Limitations also come from the competitive landscape with the patent expiration of key drugs leading to the influx of biosimilars. Areas ripe for innovation include next-generation therapies such as CAR T-cell treatments and novel drug delivery systems like nanocarrier technology. These innovations can improve therapy specificity and reduce side effects, boosting market expansion. The market exhibits a dual nature, buoyed by scientific innovations yet constrained by economic and regulatory hurdles. Strategic alignment with regulatory frameworks, investment in cutting-edge R&D, and leveraging partnerships with biotech firms could be effective avenues for sustainable business growth and enhanced patient outcomes in the multiple myeloma drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Myeloma Drug Market

The Multiple Myeloma Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased indication and prevalence of Multiple Myeloma
  • Attractive reimbursement policies supporting treatments in developed countries
  • Increased drug availability along with approvals for generics
• Market Restraints
  • Stringent drug approval process
• Market Opportunities
  • Collaborating product development and drug trials and commercialization
  • Targeted therapy and adoption of Corticosteroids
• Market Challenges
  • Potential side effects

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Myeloma Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Myeloma Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Myeloma Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Myeloma Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Myeloma Drug Market

A detailed market share analysis in the Multiple Myeloma Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Myeloma Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Myeloma Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Myeloma Drug Market

A strategic analysis of the Multiple Myeloma Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Drug Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accurex Health Care Manufacturing Inc., Amgen Inc., Bayer AG, Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche AG, Intas Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors.
• Based on Distribution, market is studied across Hospital Pharmacy, Online Channel, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased indication and prevalence of Multiple Myeloma
    • 5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
    • 5.1.1.3. Increased drug availability along with approvals for generics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent drug approval process
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating product development and drug trials and commercialization
    • 5.1.3.2. Targeted therapy and adoption of Corticosteroids
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multiple Myeloma Drug Market, by Drug

• 6.1. Introduction
• 6.2. Histone Deacetylase Inhibitors
• 6.3. Immunomodulating Agents
• 6.4. Monoclonal Antibodies
• 6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Channel
• 7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Accurex Health Care Manufacturing Inc.
• 3. Amgen Inc.
• 4. Bayer AG
• 5. Bristol Myers Squibb Company
• 6. Celgene Corporation
• 7. F. Hoffmann-La Roche AG
• 8. Intas Pharmaceuticals Limited
• 9. Johnson & Johnson Services, Inc.
• 10. Nichi-Iko Pharmaceutical Co., Ltd.
• 11. Novartis AG
• 12. Ono Pharmaceutical Co., Ltd.
• 13. Pfizer Inc.
• 14. Sandoz International GmbH
• 15. Takeda Pharmaceutical Company Limited